INLYTA has been shown to inhibit receptor tyrosine kinases, including VEGFR-1, -2, and -3, in vitro and in preclinical models
VEGF is constitutively upregulated in RCC, making it a primary driver of the disease1,2
- Preclinical evidence demonstrates that the VEGF pathway plays a key role in continued RCC tumor growth and spread3,4
- Preclinical models suggest that the VEGF pathway contributes to tumor growth and cancer progression by stimulating pathological angiogenesis and impacting immune cell activity in the tumor microenvironment5